Freeport-McMoRan vs Newmont
FCX and NEM side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FCX and NEM compare
Newmont is the larger company, worth 1.3 times as much as Freeport-McMoRan ($112B against $89.7B).
On earnings, Newmont is cheaper: it trades at 13.5× trailing earnings, against 30.8× for Freeport-McMoRan.
Newmont grew revenue faster over the last twelve months (25.2% versus 0.19% for Freeport-McMoRan).
Both pay dividends: Freeport-McMoRan yields 0.96% and Newmont 0.97%.
Newmont scores higher on the StockData Score (22 against 5 for Freeport-McMoRan), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FCX | NEM |
|---|---|---|
| Size and price | ||
| Market cap | $89.7B | $112B |
| Share price | $62.47 | $106.61 |
| Change, 1 year | 48.1% | 33.8% |
| Change, 5 years | 68.7% | 89.2% |
| Beta (5Y) | 1.45 | 0.71 |
| Employees | 29K | 18K |
| StockData Score | ||
| Total score | 5 | 22 (better) |
| Valuation score | 0 | 6 (better) |
| Growth score | 0 | 4 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 30.8× | 13.5× (better) |
| P/S | 3.5× (better) | 4.4× |
| P/B | 4.5× | 3.2× (better) |
| EV/EBITDA | 11.8× | 6.8× (better) |
| P/FCF | – | 11.5× |
| FCF yield | – | 8.7% |
| Fair value | $48.63 | $169.55 |
| Margin of safety | −28.5% | 37.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.19% | 25.2% (better) |
| Revenue growth, 5Y average | 12.8% | 14.5% (better) |
| Net income growth (TTM) | – | 37.0% |
| EPS growth (TTM) | 53.8% (better) | 42.2% |
| EPS growth, 5Y average | – | 12.7% |
| Profitability | ||
| Gross margin | 27.1% | 68.9% (better) |
| Operating margin | 26.8% | – |
| Net margin | – | 33.4% |
| FCF margin | – | 37.8% |
| Return on equity | – | 25.5% |
| Return on invested capital | 19.9% | – |
| Financial health | ||
| Debt / equity | 0.47 | 0.14 (better) |
| Net debt / EBITDA | 0.59 (better) | −0.25 |
| Current ratio | 2.07 | 2.55 (better) |
| Altman Z-score | 2.99 | 3.79 (better) |
| Piotroski F-score | – | 9 |
| Dividends and buybacks | ||
| Dividend yield | 0.96% | 0.97% (better) |
| Payout ratio | – | 12.8% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | – | −0.78% |
| Buyback yield | 0.23% | 3.9% (better) |
| Shareholder yield | 1.2% | 4.9% (better) |
| Ownership | ||
| Held by institutions | 86.9% | 79.3% |
| Held by insiders | 0.60% | 0.11% |
| Insider net buying, 12 months | −$46.0M | −$12.4M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 1.8% | – |
Go deeper
- FCX stock overview
- FCX income statement
- FCX valuation and score
- NEM stock overview
- NEM income statement
- NEM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.